30 September 2023
Latham & Watkins Advises on Immunovant’s Pricing of US$450 Million Common Stock Financing
Advising firms
Deal team
4 lawyers named| Lawyer | Firm | Seniority | Practice | Office |
|---|---|---|---|---|
| Nathan Ajiashvili Lead | Latham & Watkins LLP | Partner | capital markets | New York |
| Salvatore Vanchieri Lead | Latham & Watkins LLP | Partner | capital markets | New York |
| Egzon Sulejmani | Latham & Watkins LLP | Associate | capital markets | Not stated |
| Jie Lin Nai | Latham & Watkins LLP | Associate | capital markets | Not stated |
1 more lawyer on this deal. Register free to see the full deal team, with seniority, practice and office.
REGISTER FREE SIGN INWant co-counsel patterns, repeat clients and alerts when these firms land their next deal? Get Pro.
Stated terms
- Stated value
- USD 450m (US$450 million)
- What the figure measures
- Issue size
- Client
- Not stated
- Counterparties
- Immunovant, Inc. (Issuer)